

1 **Glycerol monolaurate ameliorated intestinal barrier and immunity in broilers by**
2 **regulating intestinal inflammation, antioxidant balance, and intestinal**
3 **microbiota**

4

5 Linglian Kong^a, Zhenhua Wang^b, Chuanpi Xiao^c, Qidong Zhu^a, Zhigang Song^{a#}

6

7 ^aDepartment of Animal Science and Technology, Shandong Agricultural University,

8 Taian, Shandong 271018, China

9 ^bCenter for Mitochondria and Healthy Ageing, College of Life Sciences, Yantai

10 University, Yantai, Shandong 264005, China

11 ^cPrecision Livestock and Nutrition Unit, Gembloux Agro-Bio Tech, University of

12 Liège, Gembloux 5030, Belgium

13

14 Running Head: GML ameliorated intestinal barrier and immunity

15

16 #Address correspondence to Zhigang Song, zhigangs@sdau.edu.cn

17 **ABSTRACT**

18 Extensive interactions occur between a poultry host and its gut microbiome. Glycerol
19 monolaurate (GML) possesses a large range of antimicrobial and immunoregulatory
20 properties. This study was conducted to investigate the impact of different doses of
21 GML (basal diets complemented with 0, 300, 600, 900, or 1200 mg/kg GML) on
22 growth performance, intestinal barrier, and cecal microbiota in broiler chicks. Results
23 revealed that feed intake increased after 900 and 1200 mg/kg GML were administered
24 during the entire 14-day experiment period. Dietary GML decreased crypt depth and
25 increased the villus height-to-crypt depth ratio of the jejunum. In the serum and
26 jejunum, supplementation with more than 600 mg/kg GML reduced interleukin-1 β ,
27 tumor necrosis factor- α , and malondialdehyde levels and increased the levels of
28 immunoglobulin G, jejunal mucin 2, total antioxidant capacity, and total superoxide
29 dismutase. GML down-regulated jejunal interleukin-1 β and interferon- γ expression
30 and increased the mRNA level of zonula occludens 1 and occludin. A reduced
31 expression of toll-like receptor 4 and a tendency of down-regulated nuclear factor
32 kappa-B was shown in GML-treated groups. In addition, GML modulated the
33 composition of the cecal microbiota of the broilers, improved microbial diversity, and
34 increased the abundance of butyrate-producing bacteria. Spearman's correlation
35 analysis revealed that the genera *Barnesiella*, *Coproacter*, *Lachnospiraceae*,
36 *Faecalibacterium*, *Bacteroides*, *Odoracter*, and *Parabacteroides* were related to
37 inflammation and intestinal integrity. In conclusion, GML ameliorated intestinal

38 morphology and barrier function in broiler chicks probably by regulating intestinal
39 immune and antioxidant balance, as well as intestinal microbiota.

40 **IMPORTANCE**

41 Antibiotic residues and resistance issues led to the ban of antibiotic growth promoters.
42 GML is considered an efficacious antibiotic growth promoter alternative for animal
43 health and has the potential to become a unique fungicide owing to its established
44 safety, antibacterial properties, and immunomodulatory capacity. Despite the potential
45 of GML as an additive in poultry feed, little is known about the influence of GML on
46 cecal microbiota in broilers. The significance of our research was to determine the
47 microbial mechanism by which GML worked.

48

49 **KEYWORDS:** glycerol monolaurate, intestinal barrier, antioxidant, inflammation,
50 microbiota

51 INTRODUCTION

52 Antibiotics play a significant role in disease prevention and growth promotion in the
53 poultry industry. Despite increasing demand for poultry, antibiotic residues and
54 resistance issues led to the ban of antibiotic growth promoters (1), pressuring the
55 industry to find alternatives for maintaining poultry flock health. One promising
56 approach is immune modulation, in which natural host mechanisms are exploited to
57 enhance and modulate bird's immune response (2). Targeted dietary supplementation
58 or using a feed additive may be useful in the immunomodulation of the immune
59 system. These ingredients can reduce the negative impacts of environmental stressors
60 on animal immune systems and production performance (3). For instance,
61 antimicrobial peptides are feed additives that neutralize lipopolysaccharide (LPS)
62 from *Pseudomonas aeruginosa* at the cellular level and significantly inhibit tumor
63 necrosis factor (TNF- α) and nitric oxide (NO) production in the macrophages of
64 LPS-treated mice (4). Extensive research has been carried out to evaluate an array of
65 products as alternatives to antibiotic growth promoters; such products, including food
66 industry by-products, plant metabolites, non-digestible oligosaccharides, natural
67 by-products, essential minerals, amino acids, medicinal herbs, organic acids, and
68 essential oils, can at least partially alter immune function in poultry (2).

69 Glycerol monolaurate (GML), a fatty acid composed of glycerol and lauric acid,
70 possesses a large range of antimicrobial and immunoregulatory properties (5).
71 Glycerol monolaurate is considered a food-safe emulsifier endorsed by the Food and
72 Drug Administration and recognized as a nontoxic compound even at relatively high

73 dose levels (6). Recent studies revealed that GML is an efficacious antibiotic growth
74 promoter alternative for animal health (7) and has the potential to become a unique
75 fungicide owing to its established safety, antibacterial properties, and
76 immunomodulatory capacity (8). Glycerol monolaurate with a supplementary dose of
77 up to 5 g/kg to basal diets can enhance the immune status and intestinal
78 histomorphology of broilers (3). In vivo, growth performance and intestinal
79 development are improved by dietary GML in mice and laying hens through intestinal
80 microbiota alteration (6).

81 Despite the potential of GML as an additive in poultry feed (9), little is known on
82 the influence of GML on intestinal barrier and cecal microbiota in broilers. Extensive
83 interactions occur between a poultry host and its gut microbiome, particularly during
84 exchange of nutrients and modulation of host gut morphology, physiology, and
85 immunity (10). We hypothesized that GML can improve immunity, growth
86 performance, and health status by altering gut microbiota. Therefore, the present study
87 was designed to investigate the effects of different doses of GML on performance,
88 immunity, and antioxidant capacity, as well as intestinal barrier and microbiota in
89 broilers.

90

91 **RESULTS**

92 **Growth performance.** As shown in Table 3, FI rates increased in the 600, 900,
93 and 1200 mg/kg GML-treated groups compared with those in the 300 mg/kg group (P
94 < 0.05) after 7–14 days of treatment but showed no significant difference from those

95 of the control group ($P > 0.05$). However, the administration of 900 and 1200 mg/kg
96 GML increased FI compared to the control and 300 mg/kg GML-treated group during
97 the overall period ($P < 0.05$). Dietary GML did not affect the BW, BWG, and FCR of
98 broiler chicks. ($P > 0.05$).

99 **Intestinal morphology analysis.** As shown in Table 4, GML decreased CD ($P <$
100 0.05) and increased VCR ($P < 0.05$) in the jejunum on day 7 and 14 with increasing
101 dose (600, 900, and 1200 mg/kg). No effect was observed on jejunal VH after dietary
102 treatment with GML ($P > 0.05$).

103 **Serum and intestinal biochemical indicators.** On days 7 and 14, dietary
104 treatment with 600, 900, and 1200 mg/kg GML reduced serum IL-1 β level ($P < 0.05$)
105 compared with the level in the control group (Table 5). A reduction ($P < 0.05$) of
106 serum TNF- α level was recorded in 7-day-old broilers treated with 900 and 1200
107 mg/kg GML. In addition, 1200 mg/kg GML increased serum IgG and jejunal mucin 2
108 levels relative to those of the control on day 14.

109 **Antioxidant capacity in serum and jejunum.** As shown in Table 6, dietary
110 GML reduced MDA content in the serum and jejunum on 14-day-old broilers ($P <$
111 0.05). Serum SOD level increased in broilers fed with 1200 mg/kg GML on day 7 (P
112 < 0.05) relative to that of the control and tended to improve 14 days after GML
113 supplementation ($P < 0.1$). In the jejunum of 7-day-old broilers, dietary treatment with
114 GML increased SOD levels ($P < 0.05$), and the highest level was found in the 1200
115 mg/kg group ($P < 0.05$). A higher T-AOC level was observed in the jejunum of the 600
116 and 1200 mg/kg groups on day 7 ($P < 0.05$) and in the sera after 900 and 1200 mg/kg

117 GML addition on day 14 ($P < 0.05$).

118 **Relative mRNA expression of jejunal genes.** On 7-day-old broilers, dietary
119 treatment with 1200 mg/kg GML down-regulated ($P < 0.05$) jejunal *IL-1 β* and
120 *interferon (IFN- γ)* expression compared with that in the control (Table 7). Moreover,
121 600 mg/kg GML-treated broilers showed higher *zonula occludens (ZO)-1* and
122 *occludin* expression levels than the control ($P < 0.05$). The mRNA level of *occludin*
123 increased in the jejunum with 1200 mg/kg GML supplementation ($P < 0.05$). On
124 14-day-old broilers, *IL-1 β* expression decreased in the 1200 mg/kg group ($P < 0.05$),
125 and *IFN- γ* expression decreased in the 600, 900, and 1200 mg/kg groups ($P < 0.05$).
126 Jejunal *occludin* expression was not altered by GML supplementation, compared with
127 that in the control ($P > 0.05$), but difference in jejunal *occludin* expression between
128 GML-treated groups was observed ($P < 0.05$). The expression of toll-like receptor4
129 (TLR4) was decreased in 600 and 1200 mg/kg GML-treated broilers ($P < 0.05$). In
130 addition, dietary GML tended to reduce the expression of jejunal nuclear factor
131 kappa-B (NF- κ B) in 14-day-old broilers ($P < 0.1$).

132 **Composition and community diversity of cecal microbiota.** On 7-day-old
133 broilers, 378 OTUs were found among the five groups, and 626, 682, 843, 818, and
134 827 specific OTUs were unique to the control, 300, 600, 900, and 1200 mg/kg
135 GML-treated groups, respectively (Fig. 1A). On 14 days of age, 938, 845, 616, 964,
136 and 973 specific OTUs existed respectively in the Con, 300, 600, 900, and 1200
137 mg/kg GML-treated groups (Fig. 1A). As shown in Table 8, diets supplemented with
138 600, 900, and 1200 mg/kg GML increased Chao 1 and observed indices in 7-day-old

139 broilers compared with the control ($P < 0.05$). However, no significant differences
140 between the control and GML-treated groups were observed for alpha diversity on
141 14-day-old broilers ($P > 0.05$). Broilers fed with 1200 mg/kg GML had the highest (P
142 < 0.05) Chao 1, PD, observed, Shannon, and Simpson indices among the
143 GML-treated groups. On day 7, unweighted UniFrac-based nonmetric
144 multidimensional scaling analysis indicated no obvious difference ($P > 0.05$) in the β
145 diversity of cecal microbiota between each group (Fig. 1B). In the 14-day-old broilers,
146 the microbiomes in the 900 and 1200 mg/kg GML groups were completely separated
147 from the control and 300 mg/kg on the NMDS2 axes ($P = 0.003$; Fig. 1B).
148 PERMANOVA analysis based on unweighted UniFrac distance revealed that the cecal
149 microbiota in the 600, 900, and 1200 mg/kg GML-treated groups had a higher β
150 diversity index than that in the control on day 7 ($P < 0.05$) and in the 900 and 1200
151 mg/kg GML-treated groups on day 14 ($P < 0.05$; Fig. 1C).

152 The relative abundance of community at the phylum level is shown in Fig. 2A.
153 At the phylum level, the *Firmicutes/Bacteroidetes* ratio decreased in the ceca of
154 7-day-old broilers after 600 and 1200 mg/kg GML supplementation ($P < 0.05$) but
155 was not altered in each group on day 14 ($P > 0.05$; Fig. 2B). Supplementation with
156 600 and 1200 mg/kg GML increased the amount of *Bacteroidetes* relative to the
157 amounts in the control, 300, and 900 mg/kg groups ($P < 0.05$; Fig. 2C). The relative
158 abundance of *Actinobacteria* decreased in the ceca of the 14-day-old broilers that
159 received 600 and 900 mg/kg GML ($P < 0.05$; Fig. 2C). At the genus level, the 300
160 mg/kg GML-treated group was enriched with *Barnesiella* and *CHKCI001* on days 7

161 and 14 ($P < 0.05$), respectively (Fig. 3B). The proportion of *Coprobacter* and reduced
162 *Lachnospiraceae_FE2018_group* (Fig. 3B) increased in the 600 mg/kg GML-treated
163 group ($P < 0.05$). The relative abundances of *Barnesiella*, *Odoribacter* and
164 *Parabacteroides* increased ($P < 0.05$) in the broilers fed with 900 mg/kg GML (Fig.
165 3B). In addition, except the decreased *Lachnospiraceae_FE2018_group*, 1200 mg/kg
166 GML significantly increased the abundances of *Barnesiella*, *Faecalibacterium*,
167 *Bacteroides*, *Odoribacter*, and *Parabacteroides* and *CHKC001* level in the ceca of the
168 broilers ($P < 0.05$) relative to those in the control and broilers that received other
169 GML doses (Fig. 3B).

170 The specific bacterial taxa associated with GML treatment was identified
171 through linear discriminant analysis effect size (LEfSe, LDA score > 4) analysis. As
172 shown in Fig. 4A, only the genus *Blautia* was observed to be significantly abundant in
173 the 300 mg/kg group. The 600 mg/kg GML-treated group showed the enrichment of
174 the genus *Coprobacter*, family *Bacteroidetes*, phylum Bacteroidia, and order
175 Bacteroidales. The family *Lactobacillaceae* and genus *Lactobacillus* predominated in
176 the 900 mg/kg GML group. Furthermore, the genera *Faecalibacterium*, *Barnesiella*,
177 and *Intestinimonas* were enriched in the ceca of 1200 mg/kg GML-treated broilers on
178 day 7. At the 14th day of treatment, the abundance of genus *UBA1819* increased in the
179 300 mg/kg GML-treated group (Fig. 4B). LEfSe analysis indicated significant
180 distinctive bacteria of family *Barnesiellaceae* and genus *Barnesiella* in the 600 mg/kg
181 GML-treated group (Fig. 4B). Genus *Arthromitus* and *CHKCI001* were
182 overrepresented in the 900 mg/kg group (Fig. 4B). The cecal microbiota in the 1200

183 mg/kg GML-fed group was characterized by phylum, family *Lachnospiraceae*, and
184 genus *Coprobacter* (Fig. 4B). Through Spearman correlation analysis, the
185 relationships of changes in intestinal microflora at the genus level with intestinal
186 integrity, inflammatory factors, antioxidant enzymes, tight junction proteins, and
187 TLR/NF- κ B signal pathway were discussed (Fig. 4C). The levels of inflammatory
188 factors were positively associated with the genera *Lachnospiraceae_UCG_008*,
189 *Erysipelatoclostridium*, *Unspecified_Bacteria*, *Anaerostipes*,
190 *Eubacterium_hallii_group*, *Eisenbergiella*, *Lachnospiraceae_UCG_010*, and
191 *Anaerotruncus* but negatively correlated with *Barnesiella*, *Faecalibacterium*,
192 *Coprobacter*, *Odoribacter*, *Parabacteroides*, *CHKCI001*, and *Bilophila*. Intestinal
193 integrity was possibly correlated with the genera *Coprobacter*,
194 *Ruminococcaceae_UCG_010*, *Faecalibacterium*, *Barnesiella*, *Desulfovibrio*,
195 *Bilophila*, *Parabacteroides*, *Phascolarctobacterium*, and *CHKCI001*. The abundances
196 of *Lachnospiraceae_FE2018_group*, *Eubacterium_hallii_group*,
197 *Ruminiclostridium_5*, *Enterococcus*, *Romboutsia*, and *Caproiciproducens* were
198 negatively associated with intestinal barrier.

199

200 **Discussion**

201 Medium-chain fatty acids (MCFA) have received widespread attention as feed
202 additives, showing positive benefits and improving animal health, production, and
203 feed digestibility (11, 12). Current evidence supports that MCFA and monoglycerides
204 are generally effective in supporting growth performance and intestinal health (13).

205 Feed intake is the basic feature that guides the growth rates of broilers (14). In the
206 current study, dietary treatment with GML effectively increased FI rates of broiler
207 chicks, consistent with previous findings (9, 15). A combination of gut inflammation,
208 immune cell infiltration, and increased levels of proinflammatory cytokines often
209 reduce FI and cause diarrhea (16). Decreased level of inflammatory factors after GML
210 treatment may be one of the reasons for the increased FI in the present study. However,
211 none of the supplemented treatment groups showed changes in BW, BWG, and FCR,
212 consistent with the previous findings that GML did not alter the growth performance
213 of broilers in the first 28 days of treatment (17). In addition, no effects were reported
214 on the BW, BWG, and FCR after dietary supplementation with four GML levels (0, 1,
215 3, or 5 g/kg) during all experimental periods (3). Conversely, increased ADFI and BW
216 and reduced FCR were observed in the 28–56-day-old yellow-feathered broilers with
217 dietary GML (18). Broilers fed with GML had increased BWG, ADG, and feed
218 consumption and decreased FCR (9). The positive effect of MCFA on digestibility and
219 growth performance is the inhibition of pathogen proliferation (19).

220 Diets complemented with the glycerol-esters of MCFAs exert
221 immunomodulatory effects (20). In the current study, reduced IL-1 β and TNF- α and
222 increased IgG levels were observed in the sera after dietary treatment with GML.
223 Proinflammatory cytokines IL-6 and TNF- β levels decreased in the sera after GML
224 supplementation, which alleviates systemic inflammatory response in
225 high-fat-diet-fed mice (6). In addition, GML may be considered a topical
226 anti-inflammatory agent (21). It down-regulated the gene expression of jejunal *IL-1 β* ,

227 *IL-6*, and *IFN- γ* in the present study. Owing to the relatively stable state and long
228 residence time in the gastrointestinal tract, an anti-inflammatory environment was
229 induced instead of systemic inflammation after the administration of a high dose of
230 GML (22). A similar result was observed in this study. The 1200 mg/kg GML dose
231 showed better effects on broiler inflammation and immunity. Monoglycerides and
232 MCFAs exhibit antimicrobial and immunomodulatory activities as additive candidates,
233 thereby mitigating feed pathogen proliferation and improving enteric health in weaned
234 pigs (13). An *in vitro* study showed that lauric acid treatment reduces the
235 concentration of proinflammatory cytokines (TNF- α , IL-6, and IL-1 β) in the culture
236 supernatant of microglia attacked by LPS (23). T cell receptor (TCR)-induced
237 signaling and T cell activation were suppressed by GML, which inhibits T
238 cell-mediated cytokine storm (24). In addition, GML disrupted the lipid dynamics of
239 human T cells, potentially reducing the TCR-induced production of cytokines. This
240 function suggests that GML has an immunomodulatory role (5). The secretion of
241 MIP-3 and IL-8 induced by HIV-1 was inhibited. This result supported the hypothesis
242 that GML has an immunomodulatory effect during infection (8).

243 One of the central ways feed compounds affect immunity is activating NF- κ B,
244 which is an inducible central regulator of inflammatory responses involved in most
245 innate immune receptor signaling pathways (25). In this study, GML supplementation
246 tended to decrease jejunal *NF- κ B* expression. Lauric acid and GML have minimal
247 impacts on NF- κ B activation in the absence of an LPS challenge, although a
248 statistically significant increase can be observed at certain concentrations (25). Such

249 increase partially explains the results of the present study. The canonical pathway of
250 NF- κ B activation involves signaling by pattern recognition receptors, such as TLR
251 (26). Our data indicated that dietary treatment with 600 and 1200 mg/kg GML
252 effectively reduced the relative mRNA expression of *TLR4*. Similar results were
253 obtained in a mice experiment in which GML down-regulated *TLR2* MyD88
254 expression in the liver, reducing systemic inflammation in high-fat-diet fed mice (6).
255 Lauric acid increases the activity of NF- κ B through the dimerization of TLR2 and
256 TLR1 or TLR6 and the activation of TLR4 (27).

257 Intestinal integrity is a key factor for preventing the invasion of pathogenic
258 microorganisms in broilers (28). Dietary GML tends to increase the VH and VCR and
259 decrease the CD of the jejunum, thus improving growth performance (18). In this
260 study, dietary GML decreased CD and increased VCR in the jejunum of broilers with
261 increasing dose. High VCR is widely regarded as a good indicator of mucosal
262 turnover and is related to strong digestion and absorption capacity (28). VH and VCR
263 in the duodenum, jejunum, and ileum of broilers increased after 150 mg/kg GML
264 supplementation, and this increase was considered the reason for the high metabolic
265 rate of feed nutrients and decreased FCR (29). Natural extracts with
266 anti-inflammatory effects restore the damaged intestinal morphology of broilers
267 attacked by LPS (30). Therefore, the improvement in intestinal integrity can be
268 partially explained by the decreased expression of proinflammatory cytokines and
269 down-regulation of *TLR4/NF- κ B* signal transduction. After GML was given to the
270 mice, the normal expression levels of *ZO-1*, *occludin*, *claudin-1*, *jam-1*, and *muc 2*

271 suggested that GML maintained the mucosal barrier and intestinal health (22). In this
272 study, dietary GML effectively benefited the jejunal muc 2 content and up-regulated
273 *ZO-1* and *occludin* expression, demonstrating the beneficial effect of GML on
274 intestinal barrier of broilers. The TNF- α and IFN- γ are related to the reduction in
275 epithelial barrier function and increases the permeability of the mucosal barrier (31).
276 The reduction in serum TNF- α level and decrease in jejunal *IFN- γ* expression in this
277 study supported the idea that GML mediates intestinal barrier function through a
278 mechanism associated with the attenuation of intestinal inflammation.

279 Oxidative stress is an important factor for the destruction of mucosal barrier
280 function (32). In the current study, reduced MDA content and increased T-SOD and
281 T-AOC activity in the sera and jejunum indicated that GML reduced lipid peroxidation
282 and improved the antioxidant capacity of the broilers. This result is in a line with a
283 previous study (33). In laying hens, increase in SOD level and reduced glutathione
284 and MDA levels were observed, suggesting that GML can decrease lipid peroxidation
285 and enhance the antioxidant capacities of broilers. These features are beneficial to
286 growth performance (17). The peroxidation level in the meat of GML-fed chickens
287 was reduced and proportional to the increase in dietary additive concentration (9).
288 Significant connections between inflammation and oxidative stress have been found.
289 These processes induce each other reciprocally, thereby establishing a vicious cycle
290 that perpetuates and propagates inflammatory response (34). In addition, the
291 proinflammatory signaling cascades triggered by TLR engagement enhance the
292 expression of iNOS, implying that TLR activation may result in oxidative stress (35).

293 Therefore, the improvement in antioxidant capacity in the GML-treated broilers may
294 be related to lowered inflammatory response and down-regulated TLR4/NF- κ B
295 pathway. Reduced oxidative stress was beneficial for relieving inflammation.

296 Intestinal microbiota contributes to the maintenance of intestinal physiological
297 structure and function, which are considered relevant to intestinal inflammation,
298 barrier function, and growth performance of a host (36). Our results showed that
299 dietary GML modulated the microbial composition in the ceca of the broilers. A rich
300 community of species enhances the stability of the intestinal microecology and may
301 be related to reduced sensitivity to bacterial invasion and intestinal inflammation (37).
302 Therefore, the alleviated intestinal inflammation of broilers may be associated with
303 the modulated structure and increased diversity of intestinal microbial community
304 structure after GML addition. At the phylum level, GML mainly altered the relative
305 frequency of *Bacteroidetes* and *Actinobacteria* in the ceca of the broilers. Increase in
306 *Actinobacteria* and *Firmicutes/Bacteroidetes* ratio is the pattern of an impaired
307 intestinal barrier (38). In this study, the cecal microbiota in GML-treated broilers was
308 characterized by decreased level of *Actinobacteria* and *Firmicutes/Bacteroidetes* ratio,
309 which may be the potential reasons for the improved intestinal barrier. In addition,
310 1200 mg/kg GML increased the amount of cecal *Bacteroidetes*, which mainly
311 contributes to the fermentation of indigestible carbohydrates to butyrate (39) and
312 exerts beneficial effects on mucosal barrier integrity through its anti-inflammatory
313 effects (40). At the genus level, the relative abundance of *Barnesiella*, *Coprobacter*,
314 *Lachnospiraceae*, *Faecalibacterium*, *Bacteroides*, *Oriacter*, *Parabacteroides*, and

315 *CHKCI001* were higher in the GML-treated groups, especially under the dose of 1200
316 mg/kg. Mice fed with 400 and 800 mg/kg GML had higher abundances of *Barnesiella*,
317 which was considered to be positively associated with a healthy state (22).
318 *Lachnospiraceae* can promote health by producing host nutrients and providing an
319 energy supply to the colonic epithelium, as well as maintaining host immune
320 homeostasis (41). *Parabacteroides* are associated with T-cell differentiation by
321 enhancing and maintaining the IL-10-producing Treg cells (42). *Barnesiella*,
322 *Faecalibacterium*, *Bacteroides*, *Odoribacter*, and *Parabacteroides* were positively
323 correlated with the level of SCFAs and produced butyrate, which exerted
324 immunomodulatory and anti-inflammatory effects by mediating the homeostasis of
325 colonic regulatory T cell populations and promoted intestinal integrity (43). In
326 addition, butyrate with antioxidant properties modulates inflammatory response by
327 inhibiting NF- κ B and provides energy to the intestinal epithelial cells (38). A
328 significant impact was reported on host health and physiology after GML
329 supplementation, which directly acts on the intestinal microbiota and considerably
330 affects metabolism and immunity (44). Therefore, the increased abundance of
331 butyrate-producing bacteria after GML addition was associated with alleviated
332 intestinal inflammation and improved intestinal morphology of the broilers.

333 In conclusion, dietary GML ameliorated intestinal morphology and barrier
334 function of broiler chicks by ameliorating inflammation and promoting antioxidant
335 status. Our results confirmed the immunomodulatory, antioxidant, and
336 anti-inflammatory properties of GML, which may be associated with the suppression

337 of the TLR4/NF- κ B signaling pathway. The altered structure of the cecal microbiota
338 manipulated by GML may be the main reason for the promotion of intestinal health in
339 the broilers.

340

341 **Material and methods**

342 **Animals, experimental design and management.** All experimental procedures
343 were approved by the Ethics Committee of the Shandong Agricultural University and
344 carried out according to the Guidelines for Experimental Animals of the Ministry of
345 Science and Technology (Beijing, People's Republic of China). All feeding and
346 euthanasia procedures were performed with full consideration of animal welfare. A
347 total of 360 one-day-old broilers (Arbor Acres) with an average weight of 45.7 g were
348 randomly divided into five groups as follows: basal diet (control) and basal diets
349 supplemented with 300, 600, 900, or 1200 mg/kg GML, which was purchased from
350 Henan Zhengtong Food Technology Co., Ltd (Henan, China) with purity of more than
351 90%. The additive dosage of GML was optimized according to previous studies (6, 45,
352 46). Each group contained six replicates (cage) of 12 broilers per cage. The
353 ingredients and nutrients levels in the basal diet were formulated according to
354 standards of the National Research Council 2012 (Table 1). All broilers were weighed
355 and randomly assigned to 30 metal cages (70 cm \times 70 cm \times 40 cm), which were
356 equipped with feeders and nipple drinkers. Broilers with similar initial weights were
357 reared in an environmentally controlled room. The temperature was 35 °C initially,
358 and then gradually decreased to 28 °C until the end of the 14-day experiment period.

359 In the first 3 days, average relative humidity was maintained at approximately 70%,
360 and thereafter maintained between 55% and 65%. In the first week, the broilers were
361 kept under 23 h of light and 1 h of darkness, which were then gradually reduced to 20
362 and 4 h, respectively.

363 **Growth performance.** On days 7 and 14, feed consumption in each replicate
364 and body weight were recorded. Body weight gain (BWG) and feed intake (FI) were
365 calculated subsequently. Spilled feed was carefully collected and weighed for the
366 correction of the final FI data. Feed conversion rate (FCR) was defined as FI:BWG.
367 The data of mortality were recorded and included in the FCR calculation.

368 **Sampling.** Two broilers per replicate were randomly selected for sampling after
369 growth performance was determined on 7 and 14 days of age. Blood samples were
370 collected from wing veins and negotiated to glass tubes without anticoagulants, then
371 centrifuged at 3000 rpm for 10 min at 4 °C. Serum was obtained and stored at -20 °C
372 for biochemical analysis. Broilers were slaughtered by cervical dislocation after blood
373 samples were obtained. Approximately 2 cm segments were excised from the jejunum
374 (from the entry point of the bile duct to the Meckel's diverticulum), flushed repeatedly
375 with cold saline solution, and immediately immersed in 4% paraformaldehyde
376 solution for histological examination. Tissue samples (1–2 g) were collected from the
377 jejunum, rapidly frozen in liquid nitrogen, and stored at -80 °C for molecular analysis.
378 The cecum was collected on ice, frozen quickly in liquid nitrogen, transported to the
379 laboratory in a dry-ice bag, and then stored at -80 °C for further microbial analysis.

380 **Jejunal morphology analysis.** Jejunum segments were fixed in 4%

381 paraformaldehyde solution for 24 h, dehydrated, and embedded in paraffin. Tissue
382 sections with 5 μm thickness were cut using a microtome (Leica RM2235, Leica
383 Biosystems Inc., Buffalo Grove, USA), fixed on slides, and stained with hematoxylin
384 and eosin. The images of the jejunum were analyzed with ImageJ analysis software
385 (Version 1.47, Bethesda, MD, USA). Ten intact villi were selected randomly from
386 each section for morphology measurement. Villus height (VH) was gauged from the
387 tip of the villus to the villus–crypt junction. Crypt depth (CD) was defined as the
388 depth of the invagination between adjacent villi. Villus height-to-crypt depth ratio
389 (VCR) was calculated. The mean value of ten values attributed to individual broilers
390 was used in statistical analysis.

391 **Biochemical assay of serum and jejunum.** Immune response status in the sera
392 was estimated by detecting the levels of interleukin 1 beta (IL-1 β), interleukin 6
393 (IL-6), tumor necrosis factor-alpha (TNF- α), and immunoglobulin G (IgG) with
394 ELISA kits (MLBIO Co., Ltd., Shanghai, China). All determination procedures were
395 performed strictly according to the manufacturer's instructions. The inter- and
396 intra-assay coefficients of variation (CVs) were less than 10%. The jejunal samples
397 were weighed accurately (0.3 g), homogenized with 2.7 ml phosphate-buffered saline
398 in a weight (g):volume (ml) ratio of 1: 9. The homogenates were centrifuged at 1000 g
399 for 10 min at 4 $^{\circ}\text{C}$, and the supernatants were collected for the detection of secreted
400 immunoglobulin A (sIgA) and mucin 2 levels with ELISA kits (MLBIO Co., Ltd.,
401 Shanghai, China). The results were expressed as pg/mg of protein.

402 **Antioxidant assay of serum and jejunum.** Malondialdehyde (MDA) levels,

403 total antioxidant capacity (T-AOC), and total superoxide dismutase (T-SOD) activity
404 were measured in each serum and jejunal homogenate with diagnostic kits
405 (intra-assay CV < 5%; inter-assay CV < 8%) purchased from Nanjing Jiancheng
406 Biotechnology Institute (Nanjing, China) according to the manufacturer's instructions.
407 The results were normalized to protein concentration in each jejunal homogenate.

408 **RNA isolation and real-time quantitative PCR.** The total RNA of the jejunum
409 was isolated using Trizol reagent (Invitrogen Biotechnology Inc., CA, USA). RNA
410 quality was evaluated through 1% agarose gel electrophoresis. The reverse
411 transcription of 1 µg of total RNA was performed using PrimeScript® RT reagent kit
412 with gDNA Eraser (RR047A, Takara Bio Inc., Dalian, China). The gene expression
413 was determined through RT-PCR. TB Green Premix Ex Taq (RR820A, Takara Bio
414 Inc., Dalian, China) and ABI 7500 real-time PCR systems (Applied Biosystems, CA,
415 USA) were used. The reaction program was as follows: predenaturation at 95 °C for
416 10 s, then denaturation at 95 °C for 5 s for a total of 40 cycles, and finally annealing
417 and extension at 60 °C for 40 s. Each reaction was repeated three times, and the
418 primer sequences are shown in Table 2. The amplification efficiency of the primers
419 was calculated with a standard curve. The specificity of the amplified products was
420 verified with the melting curve. The relative expression of the target gene was
421 analyzed through the $2^{-\Delta\Delta C_t}$ method after normalization against the geometric mean of
422 the expression of β -actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
423 TATA-binding protein (TBP).

424 **16S rRNA sequencing and analysis.** Total DNA was extracted from cecal

425 contents with an E.Z.N.A.® Soil DNA kit (Omega Bio-Tek, Norcross, GA, U.S.)
426 according to the manufacturer's instructions. DNA purity and concentration were
427 evaluated with a Nano Drop2000 spectrophotometer (Thermo Scientific, Wilmington,
428 USA), and DNA integrity was detected through 1% agarose gel electrophoresis.
429 Bacterial 16S rRNA gene spanning the V3-V4 hypervariable regions were amplified
430 with primers 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and 806R
431 (5'-GGACTACHVGGGTWTCTAAT-3') with a PCR system. PCR reactions were
432 performed in triplicate with a 20 µl mixture consisting of 4 µl of 5 × FastPfu Buffer, 2
433 µl of 2.5 mM dNTPs, 0.8 µl of each primer (5 µM), 0.4 µl of FastPfu polymerase, and
434 10 ng of template DNA. The amplification programs were set in ABI GeneAmp®
435 9700 system (ABI, USA) as follows: 3 min at 95 °C, 27 cycles of 30 s at 95 °C, 55 °C
436 for 30 s, and 72 °C for 45 s, and 72 °C for 10 min. The PCR products were detected
437 through 2% agarose gel electrophoresis and purified with an AxyPrep DNA gel
438 recovery kit (Axygen Biosciences, Union City, CA, USA) and then quantified with a
439 QuantiFluor™-ST blue fluorescence quantitative system (Promega, USA). Purified
440 amplicons were pooled in equimolar amounts, and their paired-end reads were
441 sequenced on an Illumina MiSeq PE300 platform (Illumina, San Diego, USA) by
442 Majorbio Bio-Pharm Technology Co., Ltd. (Shanghai, China). Raw fastq files
443 obtained through MiSeq sequencing were demultiplexed, quality-filtered, trimmed,
444 de-noised with trimmomatic, and merged according to the overlapping relationship by
445 FLASH (version 1.2.11, <https://ccb.jhu.edu/software/FLASH/index.shtml>). The
446 filtered reads were clustered into operational taxonomic units (OTUs) with a 97 %

447 sequence identity with UPARSE (version 7.1, <http://www.drive5.com/uparse/>).
448 Chimera was removed during clustering. The OTU representative sequence was
449 analyzed with the RDP Classifier (version 2.2,
450 <http://sourceforge.net/projects/rdp-classifier/>) against the Silva 16S rRNA database
451 (release119, <http://www.arb-silva.de>) at a confidence threshold of 70%.

452 **Statistical analysis.** Data were presented as mean \pm SD. All data were checked
453 for normality with Shapiro–Wilk test (95% confidence level). Statistical differences
454 between groups were analyzed with one-way ANOVA with Tukey’s multiple
455 comparisons or by the non-parametric factorial Kruskal-Wallis test. SPSS software
456 (SPSS 26.0, SPSS, Chicago, USA) was used. Differences were considered
457 significantly different at $P < 0.05$. Probability $0.05 < P < 0.1$ were defined as
458 tendencies.

459

460 **ACKNOWLEDGMENT**

461 This work was supported by the Natural Science Foundation of Shandong Province
462 (ZR2020MC170), the National Key R&D Program of China (2018YFD0501401-3),
463 and the Shandong Province Agricultural Industry Technology (SDAIT-11-08).

464

465 **REFERENCE**

466 1. Sánchez-Cordón PJ, Montoya M, Reis AL, Dixon LK. 2018. African swine fever: A
467 re-emerging viral disease threatening the global pig industry. *Veterinary journal* (London,
468 England : 1997) 233:41-48.

- 469 2. Kogut MH. 2017. Issues and consequences of using nutrition to modulate the avian immune
470 response. *Journal of Applied Poultry Research* 26:605-612.
- 471 3. Amer SA, A-Nasser A, Al-Khalaifah HS, AlSadek DMM, Abdel Fattah DM, Roushdy EM,
472 Sherief WRJA, Farag MFM, Altohamy DE, Abdel-Wareth AAA, Metwally AE. 2020. Effect
473 of Dietary Medium-Chain α -Monoglycerides on the Growth Performance, Intestinal
474 Histomorphology, Amino Acid Digestibility, and Broiler Chickens' Blood Biochemical
475 Parameters. *Animals : an open access journal from MDPI* 11.
- 476 4. Wang C, Shao C, Fang Y, Wang J, Dong N, Shan A. 2021. Binding loop of sunflower trypsin
477 inhibitor 1 serves as a design motif for proteolysis-resistant antimicrobial peptides. *Acta*
478 *Biomater* 124:254-269.
- 479 5. Zhang MS, Sandouk A, Houtman JCD. 2016. Glycerol Monolaurate (GML) inhibits human T
480 cell signaling and function by disrupting lipid dynamics. *Scientific reports* 6:30225.
- 481 6. Zhao M, Jiang Z, Cai H, Li Y, Mo Q, Deng L, Zhong H, Liu T, Zhang H, Kang JX, Feng F.
482 2020. Modulation of the Gut Microbiota during High-Dose Glycerol Monolaurate-Mediated
483 Amelioration of Obesity in Mice Fed a High-Fat Diet. *mBio* 11.
- 484 7. Fortuoso BF, Galli GM, Griss LG, Armanini EH, Silva AD, Fracasso M, Mostardeiro V,
485 Morsch VM, Lopes LQS, Santos RCV, Gris A, Mendes RE, Boiago MM, Da Silva AS. 2020.
486 Effects of glycerol monolaurate on growth and physiology of chicks consuming diet
487 containing fumonisin. *Microb Pathog* 147:104261.
- 488 8. Welch JL, Xiang J, Okeoma CM, Schlievert PM, Stapleton JT. 2020. Glycerol Monolaurate,
489 an Analogue to a Factor Secreted by , Is Virucidal against Enveloped Viruses, Including HIV-1.
490 *mBio* 11.

- 491 9. Fortuoso BF, Dos Reis JH, Gebert RR, Barreta M, Griss LG, Casagrande RA, de Cristo TG,
492 Santiani F, Campigotto G, Rampazzo L, Stefani LM, Boiago MM, Lopes LQ, Santos RCV,
493 Baldissera MD, Zanette RA, Tomasi T, Da Silva AS. 2019. Glycerol monolaurate in the diet of
494 broiler chickens replacing conventional antimicrobials: Impact on health, performance and
495 meat quality. *Microb Pathog* 129:161-167.
- 496 10. Pan D, Yu Z. 2014. Intestinal microbiome of poultry and its interaction with host and diet. *Gut*
497 *microbes* 5:108-119.
- 498 11. Jackman JA, Hakobyan A, Zakaryan H, Elrod CC. 2020. Inhibition of African swine fever
499 virus in liquid and feed by medium-chain fatty acids and glycerol monolaurate. *Journal of*
500 *animal science and biotechnology* 11:114.
- 501 12. Baltic B, Starčević M, Djordjevic J, Mrdović B, Markovic R. 2017. Importance of medium
502 chain fatty acids in animal nutrition. *IOP Conference Series: Earth and Environmental Science*
503 85:012048.
- 504 13. Jackman JA, Boyd RD, Elrod CC. 2020. Medium-chain fatty acids and monoglycerides as
505 feed additives for pig production: towards gut health improvement and feed pathogen
506 mitigation. *Journal of animal science and biotechnology* 11:44.
- 507 14. Abdollahi MR, Zaefarian F, Ravindran V. 2018. Feed intake response of broilers: Impact of
508 feed processing. *Animal Feed Science and Technology* 237:154-165.
- 509 15. Mustafa N. 2018. Biochemical Trails Associated with Different Doses of Alpha- Monolaurin
510 in Chicks. *Advances in Animal and Veterinary Sciences* 7.
- 511 16. Pié S, Lallès JP, Blazy F, Laffitte J, Sève B, Oswald IP. 2004. Weaning is associated with an
512 upregulation of expression of inflammatory cytokines in the intestine of piglets. *The Journal*

- 513 of nutrition 134:641-647.
- 514 17. Liu T, Li C, Zhong H, Feng F. 2021. Dietary medium-chain α -monoglycerides increase BW,
515 feed intake, and carcass yield in broilers with muscle composition alteration. Poultry science
516 100:186-195.
- 517 18. Liu T, Tang J, Feng F. 2020. Glycerol monolaurate improves performance, intestinal
518 development, and muscle amino acids in yellow-feathered broilers via manipulating gut
519 microbiota. Appl Microbiol Biotechnol 104:10279-10291.
- 520 19. Hong SM, Hwang JH, Kim IH. 2012. Effect of Medium-chain Triglyceride (MCT) on Growth
521 Performance, Nutrient Digestibility, Blood Characteristics in Weanling Pigs.
522 Asian-Australasian journal of animal sciences 25:1003-1008.
- 523 20. Masmeijer C, Rogge T, van Leenen K, De Cremer L, Deprez P, Cox E, Devriendt B, Pardon B.
524 2020. Effects of glycerol-esters of saturated short- and medium chain fatty acids on immune,
525 health and growth variables in veal calves. Preventive veterinary medicine 178:104983.
- 526 21. Peterson ML, Schlievert PM. 2006. Glycerol monolaurate inhibits the effects of Gram-positive
527 select agents on eukaryotic cells. Biochemistry 45:2387-2397.
- 528 22. Mo Q, Fu A, Deng L, Zhao M, Li Y, Zhang H, Feng F. 2019. High-dose Glycerol Monolaurate
529 Up-Regulated Beneficial Indigenous Microbiota without Inducing Metabolic Dysfunction and
530 Systemic Inflammation: New Insights into Its Antimicrobial Potential. Nutrients 11.
- 531 23. Nishimura Y, Moriyama M, Kawabe K, Satoh H, Takano K, Azuma Y-T, Nakamura Y. 2018.
532 Lauric Acid Alleviates Neuroinflammatory Responses by Activated Microglia: Involvement of
533 the GPR40-Dependent Pathway. Neurochemical research 43:1723-1735.
- 534 24. Zhang MS, Tran PM, Wolff AJ, Tremblay MM, Fosdick MG, Houtman JCD. 2018. Glycerol

- 535 monolaurate induces filopodia formation by disrupting the association between LAT and
536 SLP-76 microclusters. *Science signaling* 11.
- 537 25. Sivinski SE, Mamedova LK, Rusk RA, Elrod CC, Swartz TH, McGill JM, Bradford BJ. 2020.
538 Development of an macrophage screening system on the immunomodulating effects of feed
539 components. *Journal of animal science and biotechnology* 11:89.
- 540 26. Sun S-C. 2017. The non-canonical NF- κ B pathway in immunity and inflammation. *Nature*
541 *reviews Immunology* 17:545-558.
- 542 27. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA,
543 Hwang DH. 2004. Saturated fatty acid activates but polyunsaturated fatty acid inhibits
544 Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. *The Journal of biological*
545 *chemistry* 279:16971-16979.
- 546 28. Jiang J, Qi L, Lv Z, Jin S, Wei X, Shi F. 2019. Dietary Stevioside Supplementation Alleviates
547 Lipopolysaccharide-Induced Intestinal Mucosal Damage through Anti-Inflammatory and
548 Antioxidant Effects in Broiler Chickens. *Antioxidants (Basel, Switzerland)* 8.
- 549 29. Liu M, Chen X, Zhao H, Feng F. 2018. Effect of Dietary Supplementation with Glycerol
550 Monolaurate on Growth Performance, Digestive Ability and Chicken Nutritional Components
551 of Broilers. *Food Science*.
- 552 30. Shang Y, Regassa A, Kim JH, Kim WK. 2015. The effect of dietary fructooligosaccharide
553 supplementation on growth performance, intestinal morphology, and immune responses in
554 broiler chickens challenged with *Salmonella Enteritidis* lipopolysaccharides. *Poultry science*
555 94:2887-2897.
- 556 31. Cromarty R, Archary D. 2020. Inflammation, HIV, and Immune Quiescence: Leveraging on

- 557 Immunomodulatory Products to Reduce HIV Susceptibility. *AIDS research and treatment*
558 2020:8672850.
- 559 32. S L, Chaudhary S, R S R. 2017. Hydroalcoholic extract of *Stevia rebaudiana* bert. leaves and
560 stevioside ameliorates lipopolysaccharide induced acute liver injury in rats. *Biomedicine &*
561 *pharmacotherapy = Biomedecine & pharmacotherapie* 95:1040-1050.
- 562 33. Valentini J, Da Silva AS, Fortuoso BF, Reis JH, Gebert RR, Griss LG, Boiago MM, Lopes
563 LQS, Santos RCV, Wagner R, Tavernari FC. 2020. Chemical composition, lipid peroxidation,
564 and fatty acid profile in meat of broilers fed with glycerol monolaurate additive. *Food*
565 *chemistry* 330:127187.
- 566 34. Lugin J, Rosenblatt-Velin N, Parapanov R, Liaudet L. 2014. The role of oxidative stress
567 during inflammatory processes. *Biol Chem* 395:203-230.
- 568 35. Lucas K, Maes M. 2013. Role of the Toll Like receptor (TLR) radical cycle in chronic
569 inflammation: possible treatments targeting the TLR4 pathway. *Mol Neurobiol* 48:190-204.
- 570 36. Wang W, Li Z, Han Q, Guo Y, Zhang B, D'Inca R. 2016. Dietary live yeast and
571 mannan-oligosaccharide supplementation attenuate intestinal inflammation and barrier
572 dysfunction induced by *Escherichia coli* in broilers. *The British journal of nutrition*
573 116:1878-1888.
- 574 37. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S.
575 2004. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients
576 with active inflammatory bowel disease. *Gut* 53:685-693.
- 577 38. Olejniczak-Staruch I, Ciężyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak
578 A. 2021. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis.

- 579 International journal of molecular sciences 22.
- 580 39. Islam MR, Lepp D, Godfrey DV, Orban S, Ross K, Delaquis P, Diarra MS. 2019. Effects of
581 wild blueberry (*Vaccinium angustifolium*) pomace feeding on gut microbiota and blood
582 metabolites in free-range pastured broiler chickens. *Poultry science* 98:3739-3755.
- 583 40. Yu M, Mu C, Zhang C, Yang Y, Su Y, Zhu W. 2018. Marked Response in Microbial
584 Community and Metabolism in the Ileum and Cecum of Suckling Piglets After Early
585 Antibiotics Exposure. *Frontiers in microbiology* 9:1166.
- 586 41. Shi S, Qi Z, Jiang W, Quan S, Sheng T, Tu J, Shao Y, Qi K. 2020. Effects of probiotics on
587 cecal microbiome profile altered by duck *Escherichia coli* 17 infection in Cherry Valley ducks.
588 *Microb Pathog* 138:103849.
- 589 42. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer
590 K, Coffey PJ, Rudenski AY. 2013. Metabolites produced by commensal bacteria promote
591 peripheral regulatory T-cell generation. *Nature* 504:451-455.
- 592 43. Zhou Y, Wang Y, Quan M, Zhao H, Jia J. 2021. Gut Microbiota Changes and Their Correlation
593 with Cognitive and Neuropsychiatric Symptoms in Alzheimer's Disease. *Journal of*
594 *Alzheimer's disease* : JAD doi:10.3233/JAD-201497.
- 595 44. Jiang Z, Zhao M, Zhang H, Li Y, Liu M, Feng F. 2018. Antimicrobial Emulsifier-Glycerol
596 Monolaurate Induces Metabolic Syndrome, Gut Microbiota Dysbiosis, and Systemic
597 Low-Grade Inflammation in Low-Fat Diet Fed Mice. *Molecular nutrition & food research* 62.
- 598 45. Amer SA, A AN, Al-Khalaifah HS, AlSadek DMM, Abdel Fattah DM, Roushdy EM, Sherief
599 W, Farag MFM, Altohamy DE, Abdel-Wareth AAA, Metwally AE. 2020. Effect of Dietary
600 Medium-Chain α -Monoglycerides on the Growth Performance, Intestinal Histomorphology,

601 Amino Acid Digestibility, and Broiler Chickens' Blood Biochemical Parameters. *Animals*
602 (Basel) 11.

603 46. Ren C, Wang Y, Lin X, Song H, Zhou Q, Xu W, Shi K, Chen J, Song J, Chen F, Zhang S,
604 Guan W. 2020. A Combination of Formic Acid and Monolaurin Attenuates Enterotoxigenic
605 *Escherichia coli* Induced Intestinal Inflammation in Piglets by Inhibiting the NF- κ B/MAPK
606 Pathways with Modulation of Gut Microbiota. *J Agric Food Chem* 68:4155-4165.

607 **TABLE 1** Ingredient composition and nutritional components of the basal diet

Items	Content (%)
Ingredient	
Corn	60
Soybean meal (43)	28.8
Corn protein flour (60)	5.3
Salt	0.16
Baking soda	0.2
Limestone	1.3
Dicalcium phosphate	0.75
Soybean oil	2.2
Vitamin premix	0.03
Mineral premix	0.2
Choline chloride (50%)	0.1
Methionine	0.23
Lysine (70%)	0.58
Threonine (98.5%)	0.134
Phytase (20000U)	0.02
Total	100
Nutritional level	
Metabolizable energy	2850 (kcal/kg)
Crude protein	21.5
Lysine	1.26
Methionine	0.57
Calcium	0.60
Total phosphorus	0.60
Available phosphorus	0.40

608 Provided for per kilogram of compound diet: vitamin A, 12000 IU; vitamin D3,
609 5000 IU; vitamin E, 80 mg; VK, 3.2 mg; vitamin B1, 3.2 mg; vitamin B2, 8.6 mg;
610 nicotinic acid, 65 mg; pantothenic acid, 20 mg; vitamin B6, 4.3 mg; biotin, 0.22 mg;
611 folic acid, 2.2 mg; vitamin B12, 0.017 mg; I, 1.25 mg; Fe, 20 mg; Mn, 120 mg; Se,
612 0.3 mg ; Zn, 110 mg. Nutrition level was the calculated value.

613 **TABLE 2** Nucleotide sequences for real-time PCR primers

Gene	Accession Number	Primer sequence, 5'→ 3'	Product size (bp)
<i>IL-1β</i>	NM_204524.1	GGTCAACATCGCCACCTACA CATACGAGATGCAAACCAGCAA	86
<i>IL-6</i>	NM_204628.1	CCTTTCAGACCTACCTGGAATT ACTTCATCGGGATTTATCACCA	130
<i>TNF-α</i>	NM_204267.1	TGTGTATGTGCAGCAACCCGTAGT GGCATTGCAATTTGGACAGAAGT	229
<i>IFNγ</i>	NM_205149.1	TGAGCCAGATTGTTTCGATG TCCTTTTGAAACTCGGAGGA	246
<i>NF-κB</i>	XM_015285418.2	CACGGAGGCTTGATCCTGTT CCGCTGTCCTGTCCATTCTT	96
<i>TLR4</i>	NM_001030693.1	AGTCTGAAATTGCTGAGCTCAAAT GCGACGTTAAGCCATGGAAG	190
<i>ZO-1</i>	XM_015278981.2	CTTCAGGTGTTTCTCTTCCTCCTCTC CTGTGGTTTCATGGCTGGATC	131
<i>occludin</i>	NM_205128.1	GCTCTGCCTCATCTGCTTCTT CCCATCCGCCACGTTCTTC	142
<i>claudin-1</i>	NM_001013611.2	CTGATTGCTTCCAACCAG CAGGTCAAACAGAGGTACAAG	140
<i>claudin-2</i>	NM_001277622.1	CCTGCTCACCCCTCATTGGAG GCTGAACTCACTCTTGGGCT	145
<i>GAPDH</i>	NM_204305.1	GCCCAGAACATCATCCCA CGGCAGGTCAGGTCAACA	137
<i>β-actin</i>	NM_205518.1	CACCACAGCCGAGAGAGAAA CACAGGACTCCATACCCAAGAA	215
<i>TBP</i>	AF221563	AGCTCTGGGATAGTGCCACAG ATAATAACAGCAGCAAACGCTTG	134

614 *IL-1β*, interleukin 1β, *IL-6*, interleukin 6; *TNF-α*, tumor necrosis factor α, *TLR4*,
615 toll-like receptor; *NF-κB*, nuclear factor kappa-B; *IFN-γ*, interferon γ; *GAPDH*,
616 glyceraldehyde-3-phosphate dehydrogenase; *TBP*, TATA-binding protein.

617 **TABLE 3** Effects of dietary treatment on growth performance in 7- and 14-day-old
618 broilers

Items	Treatments					P-val ue
	Control	300 mg/kg	600 mg/kg	900 mg/kg	1200 mg/kg	
BW (g/bird)						
1d	45.71±0.27	45.65±0.15	45.68±0.08	45.67±0.19	45.67±0.26	0.992
7d	154.82±6.25	151.19±6.66	148.71±4.84	150±8.19	152.99±2.22	0.437
14d	401.42±8.99	389.23±8.77	392.67±16.09	392.54±7.82	397.07±16.78	0.149
FI (g/bird)						
1 to 7d	145.74±7.85	148.6±2.78	143.01±6.03	150.34±1.05	155.88±5.04	0.123
7 to 14d	354.74±13.39 ^{ab}	337.05±18.91 ^b	367.62±4.35 ^a	375.46±13.88 ^a	366.22±27.4 ^a	0.013
1 to 14d	500.04±13.3 ^{bc}	485.75±17.41 ^c	511.82±17.56 ^{ab}	525.64±6.91 ^a	521.54±14.46 ^a	0.001
BWG (g/bird)						
1 to 7d	116.11±6.15	120.54±6.75	118.05±4.87	119.33±8.06	122.32±2.34	0.44
7 to 14d	237.6±9.36	221.38±8.04	228.95±12.93	227.54±4.09	229.08±15.14	0.202
1 to 14d	356.71±9.07	343.6±8.91	347±16.11	346.88±7.66	351.4±16.93	0.155
FCR (g/g)						
1 to 7d	1.25±0.04	1.24±0.06	1.21±0.02	1.26±0.1	1.27±0.04	0.343
7 to 14d	1.49±0.07	1.56±0.1	1.62±0.03	1.62±0.09	1.56±0.12	0.18
1 to 14d	1.41±0.04	1.41±0.07	1.47±0.03	1.50±0.01	1.48±0.07	0.13

619 BW, body weight; FI, feed intake; FCR, feed conversion ratio.

620 Values were expressed as mean ± SD (n = 6).

621 ^{a,b,c} Different superscripts in the same line indicate significant differences ($P < 0.05$).

622 **TABLE 4** Effects of dietary treatment on the jejunal morphology of 7- and 14-day-old
623 broilers

Items	Treatments					<i>P</i> -value
	CON	300 mg/kg	600 mg/kg	900 mg/kg	1200 mg/kg	
7 d of age						
VH (μm)	659.86±96.54	708.71±64.12	706.49±84.1	684.76±77.11	675.15±76.88	0.824
CD (μm)	107.01±17.21 ^a	101.01±15.22 ^{ab}	83.39±16.79 ^{bc}	67.32±11.39 ^{cd}	60.48±9.82 ^d	<0.001
VCR	6.24±1.02 ^c	7.11±0.95 ^{bc}	8.66±1.45 ^b	10.34±1.62 ^a	11.3±1.51 ^a	<0.001
14 d of age						
VH (μm)	745.08±71.15	697.3±86.11	670.03±99.88	686.95±28.38	708.35±61.9	0.765
CD (μm)	102.33±12.34 ^a	89.9±7.99 ^b	73.28±0.86 ^c	66.33±4.16 ^c	69.1±6.76 ^c	<0.001
VCR	7.3±0.23 ^b	7.84±1.39 ^b	8.88±1.58 ^{ab}	10.37±0.47 ^a	10.34±1.44 ^a	0.011

624 VH, villus height; CD, crypt depth; VCR, villus height to crypt depth ratio.

625 Values were expressed as mean ± SD (n = 6).

626 ^{a,b,c,d} Different superscripts in the same line indicate significant differences (*P* < 0.05).

627 **TABLE 5** Effects of dietary treatment on biochemical indicators in the sera and jejunum
 628 of 7- and 14-day-old broilers

Items	Treatments					<i>P</i> -value
	CON	300mg/kg	600mg/kg	900mg/kg	1200mg/kg	
7 d of age (ng/mL)						
IL-1 β	597.46 \pm 33.97 ^a	559.36 \pm 45.06 ^{ab}	531.91 \pm 34.96 ^b	541.96 \pm 37.13 ^b	525.78 \pm 52.65 ^b	0.028
IL-6	29.05 \pm 2.08	28.9 \pm 1.71	28.62 \pm 1.67	29.73 \pm 1.1	29.57 \pm 1.05	0.897
TNF- α	81.36 \pm 6.26 ^a	79.03 \pm 3.78 ^{ab}	78.27 \pm 2.9 ^{ab}	75.44 \pm 7.37 ^{bc}	72.75 \pm 3.49 ^c	0.029
IgG	1934.38 \pm 153.59	1911.25 \pm 107	1832.5 \pm 175.64	1953.13 \pm 157.39	1829.38 \pm 160.03	0.35
sIgA	26.01 \pm 3.4	26.48 \pm 3.09	25.7 \pm 2.6	26.6 \pm 2.61	25.32 \pm 2.82	0.891
Muc2	213.65 \pm 8.99	209.97 \pm 8.15	201.65 \pm 13.8	202.8 \pm 17.57	197.98 \pm 13.87	0.219
14 d of age (ng/mL)						
IL-1 β	629.71 \pm 27.08 ^a	583.17 \pm 35.5 ^{ab}	566.84 \pm 39.61 ^b	543.68 \pm 56.89 ^b	560.59 \pm 51.03 ^b	0.018
IL-6	29.49 \pm 2.86	29.63 \pm 0.68	29.63 \pm 1.22	30.96 \pm 1.94	30.2 \pm 1.23	0.746
TNF- α	76.9 \pm 8.37	73.69 \pm 3.46	78.36 \pm 1.64	77.96 \pm 2.12	78.21 \pm 3.92	0.162
IgG	1898.13 \pm 195.47 ^b	1813.13 \pm 145.67 ^b	1941.88 \pm 167.71 ^{ab}	1939.38 \pm 202.95 ^{ab}	2115 \pm 212.94 ^a	0.042
sIgA	24.56 \pm 1.85	25.1 \pm 2.53	26.91 \pm 1.38	25.81 \pm 2.13	25.73 \pm 1.93	0.268
Muc 2	196.06 \pm 8.96 ^b	192.53 \pm 12.58 ^b	202.68 \pm 15.33 ^{ab}	201.31 \pm 12.18 ^{ab}	212.2 \pm 10.18 ^a	0.028

629 IL-1 β , interleukin 1 β ; TNF- α , tumor necrosis factor α ; IgG, immunoglobulin G; sIgA,
 630 secreted immunoglobulin A; Muc 2, mucin 2.

631 Values were expressed as mean \pm SD (n = 12).

632 ^{a,b,c} Different superscripts in the same line indicate significant differences ($P < 0.05$).

633 **TABLE 6** Effects of dietary treatment on antioxidant capacity in 7- and 14-day-old
634 broilers

Items	Treatments					<i>P</i> -value
	CON	300 mg/kg	600 mg/kg	900 mg/kg	1200 mg/kg	
Serum, 7 d of age						
MDA (nmol/ml)	5.88±1.87	5.29±0.68	5.99±1.36	5.67±0.43	5.08±0.68	0.303
SOD (U/ml)	67.41±14.18 ^b	77.19±15.5 ^{ab}	65.4±4.71 ^b	82.87±11.1 ^{ab}	93.84±17.69 ^a	0.039
T-AOC (mmol/ml)	0.56±0.06	0.54±0.11	0.52±0.08	0.58±0.1	0.63±0.11	0.269
14 d of age						
MDA (nmol/ml)	6.6±1.39 ^a	4.64±1.23 ^b	4.07±0.72 ^b	4.51±0.56 ^b	4.95±1.12 ^b	0.005
SOD (U/ml)	72.51±6.54	84.33±28.02	89.43±9.3	101.29±26.88	111±21.96	0.071
T-AOC (mmol/ml)	0.41±0.05 ^b	0.47±0.05 ^{ab}	0.49±0.11 ^{ab}	0.52±0.04 ^a	0.5±0.04 ^a	0.005
Jejunum, 7 d of age						
MDA (nmol/mgprot)	0.36±0.17	0.65±0.36	0.84±0.67	0.69±0.47	0.65±0.28	0.170
SOD (U/mgprot)	2.47±0.48 ^d	3.35±0.55 ^c	4.11±0.95 ^{ab}	3.6±0.59 ^{bc}	4.49±0.84 ^a	<0.001
T-AOC (mmol/mgprot)	0.08±0.01 ^b	0.1±0.02 ^b	0.12±0.03 ^a	0.1±0.02 ^b	0.16±0.08 ^a	0.029
14 d of age						
MDA (nmol/mgprot)	0.98±0.21 ^a	0.6±0.08 ^b	0.56±0.16 ^b	0.55±0.16 ^b	0.6±0.14 ^b	<0.001
SOD (U/mgprot)	3.72±0.65	3.77±0.7	3.76±0.9	4.01±0.74	3.39±0.55	0.556
T-AOC (mmol/mgprot)	0.08±0.01	0.08±0.01	0.08±0.02	0.08±0.02	0.07±0.01	0.686

635 MDA, malondialdehyde; SOD, superoxide dismutase; T-AOC, total antioxidant
636 capacity; mgprot, mg of protein.

637 Values were expressed as mean ± SD (n = 12).

638 ^{a,b,c,d} Different superscripts in the same line indicate significant differences (*P* < 0.05).

639 **TABLE 7** Effects of dietary treatment on jejunal gene expression of 7- and
640 14-day-old broilers

Item	Treatment					P-value
	CON	300 mg/kg	600 mg/kg	900 mg/kg	1200 mg/kg	
7 d of age						
<i>IL-1β</i>	1±0.19 ^a	0.77±0.23 ^{ab}	0.96±0.25 ^a	0.8±0.34 ^{ab}	0.55±0.07 ^b	0.019
<i>IL-6</i>	1±0.24	1.49±0.23	1.55±0.35	1.32±0.16	1.16±0.27	0.281
<i>TNF-α</i>	1±0.29	1.01±0.23	0.92±0.27	0.76±0.06	0.72±0.05	0.256
<i>IFN-γ</i>	1±0.31 ^a	0.96±0.57 ^{ab}	1.28±0.33 ^a	0.85±0.32 ^{ab}	0.59±0.19 ^b	0.047
<i>ZO-1</i>	1±0.1 ^b	1.13±0.19 ^{ab}	1.31±0.17 ^a	1.17±0.21 ^{ab}	1.03±0.07 ^{ab}	0.029
<i>occludin</i>	1±0.18 ^b	1.54±0.12 ^a	1.31±0.09 ^a	1.04±0.11 ^b	1.31±0.32 ^a	0.002
<i>claudin-1</i>	1±0.13	0.99±0.18	1.29±0.34	1.02±0.35	1.35±0.66	0.374
<i>claudin-2</i>	1±0.29	0.96±0.32	1.22±0.48	1.22±0.43	1.17±0.28	0.689
<i>TLR4</i>	1±0.2	1.06±0.32	0.91±0.07	0.83±0.21	1.01±0.13	0.501
<i>NF-κB</i>	1±0.13	0.97±0.25	1.11±0.22	1.01±0.23	0.88±0.17	0.443
14 d of age						
<i>IL-1β</i>	1±0.55	0.62±0.18	0.75±0.29	0.79±0.27	0.93±0.21	0.208
<i>IL-6</i>	1±0.18 ^a	0.87±0.26 ^{ab}	0.84±0.17 ^{ab}	1.09±0.23 ^a	0.65±0.23 ^b	0.037
<i>TNF-α</i>	1±0.2	0.94±0.21	1.04±0.15	0.88±0.26	1.07±0.24	0.548
<i>IFN-γ</i>	1±0.51 ^a	0.61±0.19 ^{ab}	0.52±0.13 ^b	0.51±0.25 ^b	0.45±0.23 ^b	0.019
<i>ZO-1</i>	1±0.08	1.02±0.16	1.13±0.18	1.2±0.25	1.34±0.35	0.111
<i>occludin</i>	1±0.12 ^{abc}	0.86±0.19 ^{bc}	0.77±0.16 ^c	1.26±0.13 ^a	1.13±0.2 ^{ab}	0.001
<i>claudin-1</i>	1±0.37	0.92±0.25	0.88±0.18	1.09±0.36	0.84±0.21	0.494
<i>claudin-2</i>	1±0.16	0.99±0.15	1±0.26	1.24±0.39	1.24±0.44	0.419
<i>TLR4</i>	1±0.35 ^a	0.69±0.18 ^{ab}	0.63±0.15 ^b	0.82±0.14 ^{ab}	0.65±0.09 ^b	0.049
<i>NF-κB</i>	1±0.33	0.7±0.12	0.79±0.08	0.84±0.13	0.8±0.17	0.093

641 *IL-1β*, interleukin 1β, *IL-6*, interleukin 6; *TNF-α*, tumor necrosis factor α, *TLR4*,
642 toll-like receptor; *NF-κB*, nuclear factor kappa-B; *IFN-γ*, interferon γ; *GAPDH*,
643 glyceraldehyde-3-phosphate dehydrogenase; *TBP*, TATA-binding protein.

644 Values were expressed as mean ± SD (n = 6).


645 ^{a,b,c} Different superscripts in the same line indicate significant differences ($P < 0.05$).

646 **TABLE 8** Effects of GML on cecal microbiota α -diversity of broilers

Item	Treatment					P-value
	CON	300mg/kg	600mg/kg	900mg/kg	1200mg/kg	
7 d of age						
Chao 1	410.11±33.93 ^b	435.31±78.4 ^{ab}	497.67±53.9 ^a	506.31±71.22 ^a	501.08±61.47 ^a	0.029
Pd	28.09±2.25 ^{ab}	27.39±4.35 ^{ab}	26.76±3.77 ^b	27.28±1.88 ^b	31.02±2.54 ^a	0.112
Observed	409.67±34 ^b	434.17±78.23 ^{ab}	496.33±54.08 ^a	505±70.25 ^a	499.5±60.82 ^a	0.029
Shannon	6.22±0.31	6.29±0.62	6.67±0.6	6.7±0.59	6.6±0.42	0.393
Simpson	0.96±0.01	0.96±0.03	0.97±0.02	0.97±0.02	0.97±0.01	0.649
14 d of age						
Chao 1	548.04±45.24 ^a	550.24±83.38 ^a	452.16±48.86 ^b	548.93±109.31 ^{ab}	612.15±45.41 ^a	0.018
Pd	34.35±13.06 ^{ab}	32.23±8.92 ^{ab}	28.18±2.59 ^b	32.16±4.49 ^{ab}	35.03±4.08 ^a	0.111
Observed	547.33±45.56 ^a	548.67±83.56 ^a	451.33±48.63 ^b	547.33±109.79 ^{ab}	611±45.22 ^a	0.018
Shannon	5.36±0.57 ^a	5.03±1.01 ^{ab}	4.51±0.36 ^b	4.99±0.51 ^{ab}	5.57±0.46 ^a	0.033
Simpson	0.89±0.06 ^{ab}	0.83±0.13 ^{ab}	0.85±0.04 ^b	0.87±0.02 ^b	0.91±0.03 ^a	0.153


647 Values were expressed as mean ± SD (n = 6).

648 ^{a,b} Different superscripts in the same line indicate significant differences according to
 649 the Kruskal-Wallis test ($P < 0.05$).




650


651 **FIG 1** Dietary GML altered the composition and community diversity of cecal
 652 microbiota. (A) Venn diagram between treatments on OTUs level. (B) NMDS
 653 analysis based on unweighted Unifrac distance. (C) PERMANOVA analysis based on
 654 unweighted Unifrac distance. Con, basal diet; G300, 600, 900, and 1200, basal diets
 655 complemented with 300, 600, 900, or 1200 mg/kg GML.



656

657 **FIG 2** Alteration of cecal microbiota on the phylum level. (A) The top 20 phyla in the
658 relative abundance of each group. (B) The ratio of Firmicutes/Bacteroidetes. (C)
659 Relative abundance of *Bacteroidetes* and *Actinobacteria*. Different superscripts
660 indicate significant differences according to the Kruskal-Wallis test ($P < 0.05$). Con,
661 basal diet; G300, 600, 900, and 1200, basal diets complemented with 300, 600, 900,
662 or 1200 mg/kg GML.





670

671 **FIG 4** (A) LEfSe analysis of cecal microbiota (LDA score is greater than 4). (B)

672 Heatmap of correlation among cecal microbiota, inflammatory factors, tight junctions,

673 antioxidant enzymes, and intestinal integrity by Spearman analysis. * $P < 0.05$, ** $P <$

674 0.01, *** $P < 0.001$. Con, basal diet; G300, 600, 900, and 1200, basal diets

675 complemented with 300, 600, 900, or 1200 mg/kg GML.